Endothelial damage and subsequent clotting is common in critical COVID-19 patients. Clots in the small vessels of not only the lungs, but also in the heart, the liver, and the kidneys are noticed in these patients. It is believed that COVID-19 can activate the coagulation cascade through various mechanisms, leading to severe hypercoagulability. Early anticoagulation may block clotting formation and reduce microthrombus, thereby reducing the risk of major organ damages.
At this time, there are no specific vaccines or treatments for COVID-19. However, there are many ongoing clinical trials evaluating potential treatments. More than 200 clinical trials have been organized mainly for the study of anti-viral drugs.
Ayass Bioscience, LLC research and development has, over the years, published many articles on the coagulation cascade and antiphiospholipids. With years of experience in treating patients with autoimmune diseases and coagulopathy, Dr. Ayass has stated that all people with positive COVID-19 can be saved if we pay attention to their vascular components, including Factors II, VII, VIII, IX, X, XI, and XII, plasminogen inhibitor, fibrinogen, HsC-Reactive Protein and D-Dimer. By monitoring these components, we can direct the therapy toward recirculating the lungs. He believes that physicians should follow anticoagulation management protocols not only for treatment of patients, but also as a preventative measure.